CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group - 16/08/11
, Lorenz Trümper, ProfMD b, Anders Österborg, ProfMD c, Ruth Pettengell, ProfMD d, Marek Trneny, MD e, Kevin Imrie, MD f, David Ma, MD g, Devinder Gill, MD h, Jan Walewski, MD i, Pier-Luigi Zinzani, MD j, Rolf Stahel, ProfMD k, Stein Kvaloy, ProfMD l, Ofer Shpilberg, ProfMD m, Ulrich Jaeger, ProfMD n, Mads Hansen, ProfMD o, Tuula Lehtinen, ProfMD p, Armando López-Guillermo, MD q, Claudia Corrado, MD r, Adriana Scheliga, MD s, Noel Milpied, ProfMD t, Myriam Mendila, MD u, Michelle Rashford u, Evelyn Kuhnt v, Markus Loeffler, ProfMD wfor the MabThera International Trial (MInT) Group‡
Summary |
Background |
The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined. We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients.
Methods |
824 patients who were from 18 countries; aged 18–60 years; and who had no risk factors or one risk factor according to age-adjusted International Prognostic Index (IPI), stage II–IV disease, or stage I disease with bulk were enrolled. These patients were randomly assigned to six cycles of CHOP-like chemotherapy and rituximab (n=413) or to six cycles of CHOP-like chemotherapy alone (n=411). Bulky and extranodal sites received additional radiotherapy. The primary endpoint was event-free survival; secondary endpoints were response, progression under therapy, progression-free survival, overall survival, and frequency of toxic effects. Analyses were done by intention to treat and per protocol. This trial is registered at www.clinicaltrials.gov, NCT 00064116.
Findings |
After a median follow-up of 34 months (range 0·03–61), patients assigned chemotherapy and rituximab had increased 3-year event-free survival compared with those assigned chemotherapy alone (79% [95% CI 75–83] vs 59% [54–64]; difference between groups 20% [13–27], log-rank p<0·0001), and had increased 3-year overall survival (93% [90–95] vs 84% [80–88]; difference between groups 9% [3–13], log-rank p=0·0001). Event-free survival was affected by treatment group, presence of bulky disease, and age-adjusted IPI: after chemotherapy and rituximab, a favourable subgroup (ie, IPI=0, no bulk) could be defined from a less-favourable subgroup (ie, IPI=1 or bulk, or both). Groups did not differ in the frequency of adverse events.
Interpretation |
Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma. The definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
Le texte complet de cet article est disponible en PDF.Plan
Vol 7 - N° 5
P. 379-391 - mai 2006 Retour au numéro
Article précédent
- The mysteries of mortality
- Talha Burki
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
- Walter Stummer, Uwe Pichlmeier, Thomas Meinel, Otmar Dieter Wiestler, Friedhelm Zanella, Hans-Jürgen Reulen, for the ALA-Glioma Study Group ‡
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?